Home
Clinical Trials
A Study of Xeloda (Capecitabi...

A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer

Last Updated: 2016-04-01

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

627 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-07-31

Study Completion Date

2006-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This 2 arm study will assess the efficacy and safety of intermittent oral Xeloda, or iv fluorouracil/leucovorin, in combination with intravenous Eloxatin (oxaliplatin) in patients previously treated for metastatic colorectal cancer. Patients will be randomized to receive either 1)XELOX (Xeloda 1000mg/m2 po bid on days 1-15 + oxaliplatin) in 3 week cycles or 2) FOLFOX-4 (oxaliplatin + leucovorin + 5-FU in 2 week cycles. The anticipated time on study treatment is until disease progression, and the target sample size is 500+ individuals.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer

NCT00069121

Colorectal Cancer

COMPLETED PHASE3

A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer

NCT00009737

Colorectal Cancer

COMPLETED PHASE3

Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan

NCT00016978

Colorectal Cancer

COMPLETED PHASE2

Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

NCT00006115

Colorectal Cancer

UNKNOWN PHASE2

Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer

NCT00016198

Colorectal Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

XELOX

Participants received XELOX (oxaliplatin and capecitabine). Oxaliplatin was administered 130 mg/m\^2 intravenous (IV) infusion over 2 hours (every 3 weeks \[Day 1\]) before the first dose of capecitabine. Capecitabine was administered orally within 30 minutes after the end of a meal (breakfast and dinner) at a dose of 1000 mg/m\^2 twice-daily (equivalent to a total daily dose of 2000 mg/m\^2), with first dose the evening of Day 1 and last dose the morning of Day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment) for up to 8 cycles (24-weeks).

Group Type EXPERIMENTAL

Oxaliplatin

Intervention Type DRUG

As prescribed, in 3 week cycles

capecitabine [Xeloda]

Intervention Type DRUG

1000mg/m2 po bid on days 1-15 of each 3 week cycle

FOLFOX-4

Participants received FOLFOX-4 (combination of oxaliplatin, leucovorin \[LV\] and 5-fluorouracil \[5-FU\] combination). Oxaliplatin was administered as an 85 mg/m\^2 IV infusion over 2 hours (on Day 1 only); with LV infusion as 200mg/m\^2 over 2 hours followed by 5-FU, given as 400mg/m\^2 bolus injection over 2-4 minutes, and then as a 600 mg/m\^2 continuous infusion over 22 hours. On Day 2, Leucovorin 200 mg/m\^2 (alone), followed by 5-FU 400 mg/m\^2 bolus injection over 2-4 minutes, and 5-FU 600 mg/m\^2 continuous infusion was repeated over 22 hours. It was (2-week cycles comprising 48 hours of infusion and 12 days of rest) for up to 12 cycles (24- weeks).

Group Type ACTIVE_COMPARATOR